Adding Talazoparib to Enzalutamide Prolongs Imaging-Based PFS in Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer with Alterations in HRR Genes By Ogkologos - June 15, 2026 121 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC MOST POPULAR Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in... October 22, 2025 ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... January 31, 2022 Droplet Transmission vs. Airborne… What’s the difference? August 10, 2020 Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α April 1, 2021 Load more HOT NEWS How we are working with industry to translate research into real... Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously... EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... Can Having Solar Panels or Living Near a Solar Farm Increase...
